Immunogenicity of therapeutic proteins: clinical implications and future prospects.
about
Assessing the Immunogenicity of BiopharmaceuticalsBiosafe nanoscale pharmaceutical adjuvant materialsGenetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced immunoreactivityLarge-scale production of functional human serum albumin from transgenic rice seedsEffect of vaccine administration modality on immunogenicity and efficacy.Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsBiosimilars: company strategies to capture value from the biologics marketAmino acid deprivation using enzymes as a targeted therapy for cancer and viral infectionsAnticalins as an alternative to antibody technology.Pharmacokinetic characteristics of therapeutic antibodies.Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties.Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice.Immunogenicity of mAbs in non-human primates during nonclinical safety assessmentOxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.Evolution of highly active enzymes by homology-independent recombination.Laboratory-directed protein evolutionRNA mutagenesis yields highly diverse mRNA libraries for in vitro protein evolution.Construction of a human antibody domain (VH) library.Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies.Optimization algorithms for functional deimmunization of therapeutic proteins.Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity.Current methods for detecting antibodies against erythropoietin and other recombinant proteins.Production of recombinant antibodies using bacteriophages.Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration.Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftAssessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administrationTherapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and developmentThe genomic sequence of the Chinese hamster ovary (CHO)-K1 cell lineIntravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responsesStabilization of proteins in solid form.Design and analysis of immune-evading enzymes for ADEPT therapy.Overcoming an optimization plateau in the directed evolution of highly efficient nerve agent bioscavengers.Original inhibition method of excessive synthesis of pro-inflammatory cytokine of tumour necrosis factor α.Factors of importance for a successful delivery system for proteins.
P2860
Q26751485-639BE20A-EED5-4A5C-98AE-1CF24A05A9D3Q26829798-9575F888-77C0-41B1-8A16-8B83DFC9A7AFQ27355448-CC68887A-3ECF-475D-A087-6619F4AEC1AAQ27675333-E5B29ED8-2106-4F2D-87B5-3F497320408DQ27692376-9730A426-7605-428E-AF98-39AE451D81EDQ28066498-C160C46E-79BE-4D52-9CC4-D820C35F8395Q28302861-E6CB32DC-94CE-49D7-B68C-F434E30E5387Q30040775-D4F917CE-E3BE-4756-881C-6EDCDA356CBDQ30160091-4657A8E4-4343-42FD-BA82-106F3EB29883Q30316517-18B6763B-A63C-441D-89FB-330123AFBAC5Q30384834-C59D47AB-F981-4858-A337-F72CCEA3F5BBQ30386156-DE75754C-5BCF-464B-A26F-D08BA7847697Q30390955-10AC63DF-3FC5-4702-942C-F537B1F4C0D4Q30402355-755548A8-8A6C-4B68-AB64-92727ADF9CC4Q30793113-2A83C56E-1061-4FD9-9277-BE6B7E7F203DQ33222949-13F7DE2E-763B-4F6B-AA03-534980862546Q33281713-1E8BD8BA-1BA0-480C-96B4-0D241B055EDDQ33413777-FDA4D056-0D1A-4656-9987-D974F7445203Q33523442-357730B5-9B06-4512-BDEA-9F73A9E70970Q33551448-F5579BD1-D789-41F8-A3A9-DEFA22387240Q33574114-581884DC-9DF9-45F5-BDC2-B306A0EA6C21Q33593537-8DB97DD5-173E-4753-B79A-4172026E50C3Q33643027-4E216C6B-8FC0-47DE-B312-F737A878246DQ33728344-3166131E-E7A7-4DFD-87D6-761A9744A1B4Q33784812-1C5C29BB-12AD-47B3-94C9-43884394C647Q33786540-4EDB0266-FC53-49F5-BC67-45DAF182CDC9Q33804009-97035B7C-A6C1-43B4-B5E7-73F47A9BCE4DQ34064079-E87FD445-1713-4FE0-9989-D59850684B9EQ34199603-7291511A-34AA-4259-AF4F-045046D4170FQ34212786-E51EE482-82F7-431F-97D4-40943BD03126Q35188192-D7212104-B471-44DB-880E-1F5303DC1A15Q35498838-C8921A4A-F247-489F-996D-BB9063334E5FQ35638576-83E34835-592B-4801-B1E3-561C60ACA9C3Q35732108-8DC4A140-DFD8-4D27-8448-0D5762BC054EQ36126960-A6D206F8-CC61-4CC0-BC95-9A7199F9F7B4Q36217972-A30B94C7-3C61-4B42-A016-064BF8CF51F0Q36254472-97E01F9F-788C-4C85-A594-9CBE6655E95DQ36270529-583EAB5E-19AC-4090-AFB0-ECBC3A435034Q36305630-849DB4D4-60FE-432A-BDF4-760DE69945B6Q36316926-D21C5510-7083-46A7-84C9-83366E3161A9
P2860
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@ast
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@en
type
label
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@ast
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@en
prefLabel
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@ast
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@en
P1476
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
@en
P2093
Huub Schellekens
P304
1720-40; discussion 1719
P356
10.1016/S0149-2918(02)80075-3
P577
2002-11-01T00:00:00Z